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Abstract 
Purpose: To evaluate the modifications of the tumor stage and clinical target volume following a prostate magnetic 
resonance imaging (MRI) to evaluate the tumor (T) staging, and the clinical benefits for prostate cancer.
Methods: A total of 410 patients with newly diagnosed and clinically localized prostate cancer were retrospectively 
analyzed. The patients were treated with definitive three-dimensional conformal radiotherapy (3D-CRT). In all of the 
patients, digital rectal examination, transrectal ultrasound, prostate biopsy and computed tomography were per-
formed to evaluate the clinical stage. Of the 410 patients, 189 patients had undergone a prostate MRI study to evalu-
ate the T staging, and 221 patients had not.
Results: Modification of the T stage after the prostate MRI was seen in 39 (25%) of the 157 evaluable patients, and a 
modification of the risk group was made in 14 (9%) patients. Eventually, a modification of the CTV in 3D-CRT plan-
ning was made in 13 (8%) patients, and 10 of these had extracapsular disease. Most of the other modifications of the 
T staging were associated with intracapsular lesions of prostate cancer which did not change the CTV. There were no 
significant differences in the biological relapse-free survival between the patients with and without a prostate MRI 
study.
Conclusions: Modification of the CTV were recognized in only 8% of the patients, most of whom had extracapsular 
disease, although that of the T stage was seen in approximately one-quarter of the patients. Prostate MRI should only 
be selected for patients with a high probability of extracapsular involvement.
Keywords: Prostate cancer, Magnetic resonance imaging, Clinical target volume, Tumor staging, Three-dimensional 
conformal radiotherapy
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Background
The standard imaging modality to evaluate the tumor (T) 
stage of the prostate cancer is currently transrectal ultra-
sound (TRUS). Recently, the use of magnetic resonance 
imaging (MRI) has been recommended for evaluating 
the T staging in patients with prostate cancer due to its 
high resolution (Turkbey et al. 2009; Barentsz et al. 2012; 
Kurhanewicz et  al. 2008). However, the sensitivity and 
specificity of local staging with MRI vary considerably 
with technique and population; with rates ranging from 
14 to 100% and 67 to 100%, respectively.
The T staging of prostate cancer plays an important 
role in planning radiotherapy (RT), as well as for pre-
dicting the prognosis. For example, in patients with T2 
or better status in the low risk group, the clinical target 
volume (CTV) in RT planning should include the entire 
prostate only, while in patients with T3 or higher stage 
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disease, the CTV should include the prostate, extraca-
psular disease and seminal vesicles. Patients with T3 or 
higher disease are more than six times more likely to 
have biochemical recurrence after radical prostatectomy 
compared to patients with T2 or better disease (Eggener 
et al. 2007).
However, there are a few clinical studies have investi-
gated whether the addition of prostate MRI for T staging 
changes the CTV and/or improves the clinical outcomes 
(Chang et al. 2014; Mullerad et al. 2004). The purpose of 
this study was to assess the modifications of the T stag-
ing and CTV following a prostate MRI to evaluate the 
T stage, and the clinical benefits in patients with newly 




From January 1998 to December 2009, 410 consecutive 
patients with primary prostate cancer were included in 
this retrospective study with the following inclusion cri-
teria: a pathologically confirmed adenocarcinoma of the 
prostate, treatment using definitive 3D-CRT with a total 
dose of 66  Gy or more, and neither nodal nor distant 
metastatic disease. The following patients were excluded: 
those who had hormone-refractory prostate cancer and 
those who underwent irradiation for the whole pelvic 
region. One hundred and eighty-nine of the 410 patients 
had undergone a prostate MRI study to evaluate the T 
staging, while the remaining 221 patients had not. The 
modifications of the tumor stage and CTV were evalu-
ated in 157 (83%) of the 189 patients who underwent the 
prostate MRI study, because the image reading reports of 
MRI, which were written by diagnostic radiologists, were 
not available in the remaining 32 patients at the time of 
the evaluation. Written informed consent for treatment 
was obtained from all patients.
The pretreatment evaluation included a complete 
history, physical examination [including digital rectal 
examination (DRE)], prostate biopsy with histological 
evaluation, laboratory studies [complete blood count, 
creatinine, alkaline phosphatase and initial prostate-
specific antigen (iPSA)]. Table  1 shows the patients’ 
clinical characteristics and treatments according to the 
use of a prostate MRI study. The risk groups were clas-
sified according to the guidelines of the National Com-
prehensive Cancer Network (NCCN) (2014) tumor 
stage. All patients had pathologically confirmed prostate 
adenocarcinoma, and 401 of 410 patients (98%) received 
neoadjuvant androgen deprivation therapy (ADT) 
(median 8.2  months; range 2.1–60.3  months); adjuvant 
ADT was continued in 128 (32%) of the 401 patients 
after the completion of RT (median 21.4  months; range 
2.2–41.0 months). The median total duration of neoadju-
vant plus adjuvant ADT was 8.5 months in 401 patients 
(range 2.1–129.0 months).
Prostate MRI and interpretation
Routine prostate imaging for a work up in patients with 
newly diagnosed prostate carcinoma included TRUS 
Table 1 The patient characteristics and  treatment meth-
ods
MRI magnetic resonance imaging, iPSA initial prostate-specific antigen, ADT 
androgen deprivation therapy.
a T stage after prostate MRI.
Prostate MRI p
Yes (n = 189) No (n = 221)
No. of patients (%) No. of patients (%)
Age, years 0.50
 Median (range) 73 (57–85) 74 (47–84)
T stagea 0.82
 T1–2 144 (76) 171 (77)
 T3–4 45 (24) 50 (23)
iPSA (ng/mL) 0.91
 <10 60 (32) 74 (33)
 10–20 57 (30) 68 (31)
 >20 71 (38) 79 (36)
 Not specified 1 (0) 0 (0)
Gleason score 0.68
 2–6 77 (41) 83 (38)
 7 65 (34) 82 (37)
 8–10 40 (21) 53 (24)
 Not specified 7 (4) 3 (1)
Risk groups 0.48
 Low 24 36
 Intermediate 60 (32) 72
 High 85 97
 Very high 16 15
 Not specified 4 1
Date of treatment <0.001
 1998–2005 117 (62) 82 (37)
 2006–2009 72 (38) 139 (63)
ADT <0.001
 <6 months 17 (9) 46 (21)
 ≥6 months 171 (90) 167 (76)
 None 1 (1) 8 (3)
Radiation dose <0.0001
 66 Gy 87 (46) 58 (26)
 70 Gy 100 (53) 162 (74)
 Other 2 (1) 1 (0)
Hyperthermia 0.53
 Yes 62 (33) 79 (36)
 No 127 (67) 142 (64)
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and computed tomography (CT). In all 410 patients 
investigated in this study, TRUS and CT was performed 
by attending urologists, and the prostate MRI had been 
additionally selected to evaluate the T stage for some 
of the patients based on the decision of each individual 
attending urologist. Therefore, although the present 
study was retrospective and non-randomized in nature, 
the subjects included patients with and without a pros-
tate MRI. Of the study population of 410 patients, 189 
patients (46%) had also undergone a prostate MRI study 
at the time of the initial diagnosis and evaluation of the 
prostate cancer, and 221 patients (54%) had not under-
gone a prostate MRI study.
Because prostate MRI was performed after DRE, TRUS 
and CT, modifications, including up- or downstaging of 
the T stage and risk group after the prostate MRI stud-
ies, were retrospectively evaluated based on the subjects’ 
medical records, including image reading reports of MRI 
in each case. The image reading reports for prostate MRI 
were written by diagnostic radiologists for each patient.
As described below, the CTV was determined according 
to the risk group. Therefore, changes in the targets added 
at upstaging or deleted at downstaging in the CTV values 
obtained before prostate MRI, as appropriate for the risk 
group before prostate MRI, and after prostate MRI, as 
actually performed in the patients, were evaluated.
Scans were performed on a 1.5-Tesla MRI scan-
ner using a phased array coil. Endorectal coils were not 
used in this study. The entire prostate gland and seminal 
vesicles were covered by axial T1-weighted spin-echo 
imaging (T1WI; repetition time/echo time, 450–550/8.4–
8.9  ms, echo train length  =  3, and the acquisition 
time was 2  min and 21  s) and axial T2-weighed turbo-
spin-echo imaging (T2WI; 3,500–3,800/85–105  ms, 
echo train length  =  17–18, and the acquisition time 
was 2  min and 34  s). These conventional images were 
obtained with a 4–5  mm slice thickness, 1.0  mm inter-
slice gap, 200–250  mm field of view and a matrix size 
of 288–256  ×  256–192. In 127 (67%) of the patients 
who underwent a prostate MRI study, gadolinium-
enhanced imaging was performed. In 104 (82%) of these 
127 patients, dynamic contrast-enhanced images were 
obtained using a 3D gradient echo sequence (LAVA; GE 
Healthcare, Milwaukee, WI, USA) with ultrafast image 
reconstruction by parallel imaging algorithms (ASSET 
factor, 2) in the axial plane (TR/TE 4.4–4.6/2.1  ms; flip 
angle, 12°, slice thickness, 3–5 mm; 320–400 mm field of 
view, matrix size of 320 × 192–256, and the acquisition 
time was 26 s).
Radiation therapy
Radiation treatment was delivered to all patients 
with definitive intent. All patients were treated with 
a 10-MV linear accelerator using three-dimensional 
conformal RT (3D-CRT) planning. Computed tomog-
raphy-assisted 3D-CRT planning (FOCUS or Xio; 
CMS Japan, Tokyo, Japan) was used to determine the 
radiation fields in all patients. All patients were treated 
in the supine position and underwent a planning CT 
scan.
A clinical target volume (CTV) was determined 
according to the risk group as follows: low risk, CTV1 
was the entire prostate alone, and CTV2 was the same as 
CTV1; intermediate risk, CTV1 was the entire prostate 
plus proximal seminal vesicles, and CTV2 was the entire 
prostate; high risk, CTV1 was the entire prostate, gross 
extracapsular disease plus proximal seminal vesicles, and 
CTV2 was the entire prostate plus gross extracapsular 
disease and very high risk, CTV1 was the entire prostate, 
gross extracapsular disease plus the entire seminal vesi-
cles, and CTV2 was the entire prostate and gross extra-
capsular disease. CT-MRI image fusion was not applied 
for the 3D-CRT planning, although prostate MRI was 
used to evaluate the T staging. Contouring of gross ext-
racapsular disease was referred based on the prostate 
MRI.
The total planning dose was 66  Gy (n  =  145), 70  Gy 
(n = 262), 72 Gy (n = 1), 74 Gy (n = 1) or 76 Gy (n = 1), 
and the fraction was 2.0 Gy once a day (five times/week) 
(1). The planning target volume (PTV) was delineated by 
contouring a CTV1 with a PTV1 margin of 1.2–1.7  cm 
during the initial 46 Gy in 23 fractions, and CTV2 with 
a PTV2 margin of 0.7–1.2  cm during the subsequent 
20–30  Gy in 10–15 fractions. The beams were shaped 
using a multileaf collimator. All patients were treated 
with 3D conformational or seven-field conformal radia-
tion with an isocentric technique.
One hundred and forty-one (34%) of the 410 patients 
were also treated with pelvic regional hyperthermia dur-
ing 3D-CRT to improve the antitumor effects of RT. 
Hyperthermia was applied after irradiation once a week 
for radio-sensitization. An 8-MHz radiofrequency (RF)-
capacitive regional hyperthermia system (Thermotron 
RF-8; Yamamoto Vinita, Osaka, Japan) was used (Abe 
et al. 1986).
Follow‑up
The length of follow-up was calculated from the date 
of the start of RT. The patients were followed-up at 1 
to 3-month intervals during the first year, and at 3 to 
6-month intervals thereafter. PSA measurement and 
assessments of the gastrointestinal and genitourinary 
morbidity were performed at each follow-up visit. Bio-
chemical failure was defined according to the Phoenix 
definition (Roach et  al. 2006). The clinical relapse-free 
survival (cRFS) was defined as the rate of freedom from 
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local failure, regional failure and distant metastasis. The 
presence of bone metastasis was confirmed by bone scin-
tigraphy, computed tomography or MR imaging. Soft tis-
sue metastasis was confirmed by computed tomography 
or MR imaging.
Statistical analysis
The Chi square tests and Mann–Whitney U tests were 
used to assess the baseline imbalances between the 
patients with and without prostate MRI. The Kaplan–
Meier method was used to calculate the outcomes for 
the biochemical relapse-free survival (bRFS) and cRFS. 
The time period was calculated as beginning at the 
start of definitive 3D-CRT. To identify prognostic fac-
tors for the bRFS, univariate analyses were performed. 
The log-rank test was used for statistical compari-
sons between groups. Multivariate analyses using the 
Cox proportional-hazards model were also performed 
to determine the bRFS. Fisher’s exact tests were per-
formed to evaluate the differences in the patterns of 
first failure between the patients with and without 
prostate MRI.
Results
Table 2 shows the results for the modifications of the T 
stage, risk group and CTV in the 3D-CRT planning fol-
lowing prostate MRI study. Upstaging of the T stage was 
identified in 33 (21%) of the 157 patients, while down-
staging was observed in six (8%) patients. Meanwhile, 
upstaging of the risk group after prostate MRI occurred 
in 10 patients, whereas downstaging was noted in four 
patients. Modifications of the CTV values were made in 
11 patients with upstaging and two patients with down-
staging after prostate MRI. Changes in the targets for 
the CTV, as added at upstaging or deleted at downstag-
ing, are listed in Table 2. Table 3 shows the relationships 
among the risk groups classified according to the Pros-
tate Cancer Risk Stratification (ProCaRS) risk group 
before prostate MRI, the upstaging of the T stage or 
NCCN risk group after prostate MRI, and the changes in 
the CTV after prostate MRI (Rodrigues et al. 2013). Eight 
(73%) of 11 patients with modifications of the CTV after 
prostate MRI who demonstrated upstaging were associ-
ated with the ProCaRS High-intermediate risk, High-risk 
or Extreme-risk groups before prostate MRI.
Table 2 A summary of the modifications for the T stage, risk group and CTV following prostate MRI studies in 157 evalu-
able patients
L low risk, IM intermediate risk, H high risk, VH very high risk, pSV proximal seminal vesicles, eSV entire seminal vesicles, GED gross extracapsular disease, CTV clinical 
target volume.
a A contour of the GED could not be depicted, because the GED confirmed or suspected in TRUS was not recognized in the prostate MRI study or by CT.
No. of  
patients (%)
No. of patients with modifications  
of the risk group after prostate MRI (%) 
(change of risk)
No. of patients with modifications of the CTV in 3D‑CRT 
planning based on the prostate MRI findings (targets 
added at upstaging or deleted at downstaging)
No change 118 (75) – –
Upstaging 33 (21) 10 (6) 11 (7)
 T1c to T2a 10 0 0
 T1c to T2b 10 1 (L → IM) 1 (pSV in CTV1)
 T1c to T2c 3 2 (L → IM) 2 (pSV in CTV1)
 T1c to T3a 2 1 (L → H) 1 (pSV and GED in CTV1, GED in CTV2)
 T2a to T3a 1 0 1 (pSV and GED in CTV1, GED in CTV2)
 T2a to T3b 2 2 (H → VH) 2 (eSV and GED in CTV1, GED in CTV2)
 T2b to T2c 1 0 0
 T2b to T3a 1 1 (IM → H) 1 (GED in CTV1, CED in CTV2)
 T2b to T3b 1 1 (H → VH) 1 (eSV and GED in CTV1, GED in CTV2)
 T3a to T4 2 2 (H → VH) 2 (eSV and GED in CTV1, GED in CTV2)
Downstaging 6 (4) 4 (3) 2 (1)
 T3a to T2a 1 1 (H → IM) 0a
 T3a to T2b 2 1 (H → IM) 0a
 T3a to T2c 1 0 0
 T3b to T2c 1 1 (VH → H) 1a (eSV in CTV1)
 T4 to T2a 1 1 (VH → H) 1a (eSV in CTV1)
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The median follow-up in all patients was 67.3 months 
(range 0.1–161.6 months), while that in the 189 patients 
with a prostate MRI study was 79.1  months (range 
0.1–161.6  months), and that in the 221 patients with-
out a prostate MRI study was 68.8 months (range 0.4–
157.8 months). Table 4 shows the prognostic factors in 
the univariate analyses for the bRFS. The 5-year and 
the 3-year bRFS were 86 and 89% in the patients with a 
prostate MRI study and 90 and 92% in the patients with-
out a prostate MRI study, respectively, and these values 
were not significantly different (Figure  1). The 5-year 
and 3-year cRFS were 96 and 98% in the patients with 
a prostate MRI study, and 97 and 99% in the patients 
without a prostate MRI study, respectively; there was 
also no significant difference in these values. In the mul-
tivariate analyses for the bRFS, the Gleason score was 
found to be a statistically significant factor, while the 
addition of the prostate MRI was not a predictive factor 
(Table 4). In the univariate subset analyses, among 315 
patients with T1–2 disease, a prostate MRI study was 
not a significant predictor of the bRFS. It was also not 
a significant predictor among the 95 patients with T3–4 
disease.
Clinical failure and biochemical failure had occurred 
in 11 and 35 patients who underwent a prostate MRI 
study, and in 6 and 26 patients without a prostate MRI 
study, respectively; there were no significant differences 
between the groups. The patterns of first failure after 
the 3D-CRT are shown in Table 5; no significant differ-
ences were seen between the patients with or without a 
prostate MRI study. Salvage ADT was performed after a 
biochemical failure in 35 (19%) patients with a prostate 
MRI study and 26 (12%) patients without a prostate MRI 
study. Death from prostate cancer was seen in two (1%) 
patients who underwent a prostate MRI and in three (1%) 
patients without a prostate MRI.
Discussion
The current study is to assess the benefits, in terms of 
the tumor staging, CTV and clinical outcomes, of add-
ing prostate MRI examinations to evaluate the T stage 
in patients with localized prostate cancer treated with 
3D-CRT. Although the current study was retrospec-
tive and non-randomized in nature, the findings were 
obtained from a large cohort of patients treated at a 
single institution. With its excellent soft-tissue resolu-
tion, MRI of the prostate clearly depicts the prostate’s 
zonal anatomy and facilitates prostate cancer locali-
zation and staging (Mullerad et  al. 2004; Graser et  al. 
2007; Yu et  al. 1997; Engelbrecht et  al. 2002). MRI 
has been shown to contribute significant incremental 
value to clinical variables in the prediction of the clini-
cal T stage, especially the existence of extracapsular 
extension and/or seminal vesicle invasion, and to sig-
nificantly improve treatment planning (Mullerad et  al. 
2004; Sala et al. 2006; Wang et al. 2004). However, some 
previous studies also demonstrate that the accuracies 
of the T staging of prostate cancer between MRI and 
TRUS were comparable (Rifkin et al. 1990; Presti et al. 
1996; Ekici et al. 1999). In the current study, modifica-
tions of the CTV for treatment planning with 3D-CRT 
based on the results of prostate MRI were made in 
only 8% of the patients. Furthermore, the addition of 
prostate MRI to TRUS did not improve the bRFS after 
3D-CRT in the patients with clinically localized pros-
tate cancer. We therefore confirmed that the clinical 
benefits of adding prostate MRI to TRUS to determine 
the T stage are limited in patients with localized pros-
tate cancer treated with 3D-CRT.
As mentioned in the “Background”, the CTV in RT 
planning for prostate cancer depends on the risk group; 
for the low risk group, the risk of seminal vesicle involve-
ment is <5%; therefore, the CTV should be restricted 
Table 3 Upstaging and changes in the CTV among the risk groups after prostate MRI according to the Prostate Cancer 
Risk Stratification (ProCaRS) risk stratification system
Very low-risk: T1–T2a AND PSA ≦6 ng/ml AND Gleason score ≦6. Low-risk: T1–T2a AND PSA >6 AND PSA ≦10 ng/ml AND Gleason score ≦6. Low intermediate-risk: 
T1–T2 AND PSA ≦20 mg/ml AND [PSA ≦10 ng/ml OR (PSA > 10 ng/ml AND {T1–T2a OR Gleason ≦6})]. High intermediate-risk: T1–T2 AND PSA ≦20 mg/ml AND [PSA 
>10 ng/ml AND (T2b/c OR Gleason 7)]. High-risk: [T3–T4 OR (PSA >20 ng/ml AND PSA <30 ng/ml) OR Gleason 8–10] AND % cores <87.5%. Extreme-risk: [(T3–T4 OR 
Gleason 8–10 OR PSA >20 ng/ml)] AND (PSA ≧30 ng/ml OR % cores ≧87.5%).
a Rodrigues et al. (2013).
ProCaRS 6 categoriesa 
before prostate MRI
Upstaging of the T stage  
after prostate MRI (n = 33) (%)
Upstaging of the NCCN  
risk group after prostate  
MRI (n = 10) (%)
Modifications of the CTV 
in 3D‑CRT planning based on the 
prostate MRI findings (n = 11) (%)
Very low-risk 1 (3) 1 (10) 1 (9)
Low-risk 3 (9) 1 (10) 1 (9)
Low intermediate-risk 8 (24) 1 (10) 1 (9)
High intermediate-risk 7 (21) 2 (20) 2 (18)
High-risk 4 (12) 3 (30) 4 (36)
Extreme-risk 10 (30) 2 (20) 2 (18)
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to the prostate only. In contrast, for the intermediate to 
high risk group, the risk of seminal vesicle involvement 
is higher (over 15%), so the proximal seminal vesicles 
should be included in the CTV, and for patients with 
proven seminal vesicle involvement (T3b), the entire 
seminal vesicle should be included in the CTV (Boehmer 
et al. 2006; Hayden et al. 2010). In addition, when gross 
extracapsular disease is recognized under the CTV, a 
margin of 2–5  mm (excluding the rectum) should be 
considered (Boehmer et  al. 2006; Hayden et  al. 2010). 
In the current study, a modification of the T stage after 
the prostate MRI was seen in 39 (25%) patients; however, 
there was a modification of the risk group in only 14 (9%) 
patients, and eventually, a modification of the CTV in 
3D-CRT planning only 13 (8%) patients. Gross extraca-
psular disease was newly found by the prostate MRI in 
only six (4%) patients, and all of them had a modification 
of the CTV in 3D-CRT-planing. Most of the other modi-
fications detected were associated with intracapsular 
lesions of prostate cancer which did not change the risk 
group or the CTV. We supposed that these factors may 
explain why the addition of prostate MRI did not corre-
late with any improvement of the clinical outcomes.
Prostate MRI adds significantly to the cost of treat-
ment when used routinely. Jager et al. (2000) reported the 
results of a decision analysis for the appropriate use of 
MRI for the preoperative staging of prostate cancer, and 
concluded that MRI staging is cost-effective for patients 
with a moderate or high prior probability of extracap-
sular disease. The clinical and pathological parameters 
predicting extracapsular disease in patients undergo-
ing a radical prostatectomy for clinically localized pros-
tate cancer have been reported in previous studies, and 
include a smaller prostate volume and positive cores for 
malignancy from both lobes after prostate biopsy (Sfoun-
garistos and Perimenis 2012). In the current study, 10 of 
the 13 patients with a modification of the CTV based 
on the prostate MRI had gross extracapsular disease. In 
addition, the modification of the CTV mainly occurred 
Table 4 Results of  the univariate and  multivariate analy-
ses of  factors associated with  the bRFS after  definitive 
radiotherapy
bRFS biochemical relapse-free survival, EBRT external beam radiation therapy, 
MRI magnetic resonance imaging, OR odds ratio, CI confidence interval.
a T stage after prostate MRI.
b Excluding 1 patient with unknown iPSA.
c Excluding 10 patients with unknown Gleason scores.
d Excluding 5 patients with an unknown risk group status.
e Excluding 9 patients without ADT.
f The 388 evaluable patients with complete factors.
n Univariate Multivariatef
5‑year (%) p OR (95% CI) p
Age (years) <0.01 1.71 (0.99–2.99) 0.06
 <70 130 82
 >71 280 90
T stagea <0.01 1.88 (0.96–3.71) 0.07
 T1–2 315 92
 T3–4 95 74
iPSA (ng/mL)b <0.01 1.76 (0.83–3.72) 0.14
 ≦20 258 91
 >20 151 82
Gleason scorec <0.01 3.06 (1.60–5.81) <0.001
 2–7 308 91
 8–10 92 75




 High-very high risk 214 83
Date of treatment 0.11 1.41 (0.66–3.02) 0.37
 1998–2005 199 90
 2006–2009 211 86
ADT (months)e 0.45 1.07 (0.47–2.44) 0.87
 <6 63 91
 ≧6 338 88
Radiation dose 0.06 1.51 (0.67–3.40) 0.32
 <70 Gy 145 85
 ≧70 Gy 265 92
Hyperthermia 0.18 1.21 (0.65–2.26) 0.54
 Yes 141 86
 No 269 88
Prostate MRI study 0.33 1.57 (0.89–2.77) 0.12
 Yes 189 86













With MRI 189 177 147 117 81 53 35
























Figure 1 The 5-year biochemical relapse-free survival rates between 
the patients with and without a prostate MRI were 86 and 90%, 
respectively; there were no significant differences.
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in the patients with high-intermediate risk, high-risk or 
extreme-risk group on ProCaRS before prostate MRI. 
Therefore, we also believed that MRI should be per-
formed for select patients with a high probability of ext-
racapsular disease.
Although phased-array MRI on a 1.5T scanner was 
used in the current study, some previous studies indicated 
that endorectal coil MRI significantly improved the T 
staging of prostate cancer (Futterer et al. 2007; Heijmink 
et al. 2007). Futterer et al. (2007) reported a comparison 
of the local staging accuracy of pelvic phased-array coil 
alone versus integrated endorectal-pelvic phased-array 
coils on a 1.5T scanner, and concluded that the use of 
endorectal-pelvic phased array coils resulted in signifi-
cant improvement of extracapsular extension accuracy 
and specificity. In addition, some studies have reported 
that the 3.0T phased-array MRI is equivalent to the 1.5T 
endorectal MRI in evaluating the local staging accuracy 
for prostate cancer, without a significant loss of imaging 
quality (Park et al. 2007; Torricelli et al. 2006). Multipara-
metric MRI, such as anatomic T2-weighted imaging with 
MR spectroscopic imaging, dynamic contrast-enhanced 
MR imaging, and diffusion-weighted imaging, also dem-
onstrated great interest in the evaluation of the prostate 
cancer (Sciarra et al. 2011). Further studies of pelvic MRI 
using these advanced techniques are therefore needed to 
evaluate the relationships between the T staging, espe-
cially for extracapsular disease, and the clinical benefits.
Our study is associated with several potential limita-
tions. First, due to the fact that the study was retrospec-
tive, the possibility of a selection bias with respect to the 
prognostic factors cannot be ruled out, although we per-
formed both univariate and multivariate analyses of the 
bRFS. Therefore, in the future, prospective studies will be 
needed to investigate the actual clinical benefits of pros-
tate MRI. Second, in the current study, modifications of 
the duration of ADT, based on the results of the addi-
tion of prostate MRI, could not be evaluated, because 
the treatment policy for ADT was variable among the 
attending urologists, although period of ADT is basi-
cally selected depending on the risk group. We believe 
that the results of prostate MRI would lead to limited or 
not modification of the period of ADT, because only 14 
(9%) patients had a change in risk group after prostate 
MRI. The duration of ADT in patients who underwent 
prostate MRI was longer than those in patients who did 
not, which may have influenced the results of the bRFS, 
although both the univariate and multivariate analyses 
demonstrated that the duration of ADT was not a sig-
nificant factor on the bDFS. Third, hyperthermia was 
added to 3D-CRT to obtain radio-sensitization in select 
patients due to the lower total dose of 3D-CRT, which 
may have led to a bias in the study. Several phase II clini-
cal trials on radiotherapy combined with hyperthermia 
showed promising results in patients with prostate can-
cer (Maluta et al. 2007; Anscher et al. 1992; Van Vulpen 
et al. 2004). However, in the current study, the addition 
of hyperthermia was not a significant factor on the bRFS. 
Fourth, patients who received early treatment were more 
likely to have undergone prostate MRI. Therefore, the fol-
low-up duration in the patients who underwent prostate 
MRI was longer than that in the patients who did not. 
The difference in the follow-up duration may have had an 
impact on the results of the bRFS, although the date of 
the treatment was not a significant factor in the univari-
ate/multivariate analyses on the bRFS (Table 4).
In summary, modifications of the CTV for treatment 
planning with 3D-CRT based on the results of prostate 
MRI were identified in only 8% of the patients in the 
present study, most of whom had extracapsular disease. 
In contrast, modification of the T stage after prostate 
MRI was observed in approximately one-quarter of the 
patients, and the addition of prostate MRI was not associ-
ated with any improvements in outcomes after 3D-CRT. 
Therefore, the clinical benefits of adding prostate MRI 
to evaluate the T stage may be limited in patients with 
Table 5 The patterns of first failure after definitive radiotherapy
Prostate MRI p
Yes (n = 189) No (n = 221)
No. of patients (%) No. of patients (%)
Biochemical failure alone 24 (13) 20 (9) 0.26
Clinical failure 9 (5) 4 (2) 0.10
 Primary alone 1 0
 Regional lymph node alone 2 0
 Distant metastasis alone 4 3
 Primary, regional and distant metastasis 1 0
 Regional lymph node and distant metastasis 1 1
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localized prostate cancer treated with 3D-CRT. Prostate 
MRI should not be performed in every patient with clini-
cally localized prostate carcinoma, but is recommended 
for the patients with a high prior probability of extracap-
sular disease.
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